Skip to main content
Lineage Cell Therapeutics Inc. logo

Lineage Cell Therapeutics Inc. — Investor Relations & Filings

Ticker · LCTX ISIN · US53566P1093 LEI · 5299002BI4W22SDF8R25 TA Manufacturing
Open in API
Filings indexed 2,777 across all filing types
Latest filing 2024-11-10 Report Publication Anno…
Country US United States of America
Listing TA LCTX

About Lineage Cell Therapeutics Inc.

https://lineagecell.com/

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel allogeneic cell therapies for unmet medical needs. The company's proprietary platform uses directed differentiation of pluripotent stem cells to manufacture specialized human cells. These "off-the-shelf" cell transplants are designed to replace or support dysfunctional cells in patients with serious conditions, aiming to restore or enhance physiological function. The therapeutic pipeline is focused on degenerative diseases of the eye, such as dry age-related macular degeneration, and neurological conditions, including spinal cord injury. The company leverages its integrated capabilities in cell line development, manufacturing, and delivery to advance its programs.

Recent filings

Filing Released Lang Actions
to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024
Report Publication Announcement Classification · 98% confidence The document explicitly states its purpose: "Lineage Cell Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024". It is an announcement about the future release of financial results. The document is short (2079 characters) and references an attached PDF file containing the actual information ("Attached hereto is a report on...*Third_Quarter_2024_FR_on_November_14_2024_isa.pdf*"). According to Rule 2 (The "MENU VS MEAL" RULE), a short announcement about the publication of a report should be classified as a Report Publication Announcement (RPA). This is distinct from an Earnings Release (ER), which would contain the actual results highlights.
2024-11-10 English
Major Shareholding Notification 2024
Major Shareholding Notification
2024-11-08 English
Major Shareholding Notification 2024
Major Shareholding Notification
2024-10-22 English
4
Director's Dealing
2024-08-20 English
FORM10-Q-Quarterly report which provides a continuing view of a company's financial position
Interim / Quarterly Report Classification · 100% confidence The document is explicitly titled 'FORM 10-Q' and is a 'QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934'. It contains financial statements, management's discussion and analysis, and other required disclosures for the quarterly period ended June 30, 2024. This fits the definition of an Interim / Quarterly Report (IR). H1 2024
2024-08-11 English
FORM10-Q-Quarterly report which provides a continuing view of a company's financial position
Report Publication Announcement Classification · 100% confidence The document is a short regulatory filing (under 2,100 characters) from the Israel Securities Authority (MAGNA system) that explicitly states 'Attached hereto is a report on Quarterly report... FORM_10-Q_isa.pdf'. Per the 'Menu vs Meal' rule, this is an announcement of a report rather than the report itself. Therefore, it is classified as a Report Publication Announcement (RPA). Q2 2024
2024-08-11 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.